1.20
-0.04(-3.23%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.15 |
| Day High | 1.23 |
| Day Low | 1.17 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.86 |
| Volume | 85,053 |
| Average Volume | 458,150 |
| Market Cap | 32.58M |
| PE | -1.41 |
| EPS | -0.85 |
| Moving Average 50 Days | 1.41 |
| Moving Average 200 Days | 1.19 |
| Change | -0.04 |
If you invested $1000 in Femasys Inc. (FEMY) since IPO date, it would be worth $100 as of April 22, 2025 at a share price of $1.2. Whereas If you bought $1000 worth of Femasys Inc. (FEMY) shares 3 years ago, it would be worth $764.33 as of April 22, 2025 at a share price of $1.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
GlobeNewswire Inc.
Mar 19, 2025 1:20 PM GMT
Femasys continues to expand access and market share for its first-line infertility treatment optionATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
GlobeNewswire Inc.
Mar 18, 2025 1:00 PM GMT
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedi
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
GlobeNewswire Inc.
Mar 13, 2025 12:30 PM GMT
First-in-world approval of FemBloc delivery system for women seeking permanent birth controlATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's healt